SoftBank China Venture Capital and Legend Capital contributed to a round that boosted the cancer screening device maker's overall funding to more than $100m.

China-based cancer screening product developer New Horizon Health has received $66m in a series C round that included SoftBank China Venture Capital (SBCVC), a subsidiary of telecommunications and internet group SoftBank, ChuangJianHui has reported.

Legend Capital, the venture capital firm established by conglomerate Legend Holdings, also participated in the round, which was led by private equity firm VMS Investment Group.

Founded in 2013, New Horizon Health supplies products that enable customers to test for early signs of rectal and lung…